This is a working overview of counter-ion, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-25. Anything still debated is marked as such rather than presented as settled.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
== Disease cycle == P. expansum infects a fruit via wounds through which the conidia are able to enter. Usually, puncturing, bruising, and limb rubs occur during harvesting, packaging, and processing of the fruit, all of which provide sites through which spores can enter the fruit. Conidia can be found in soil, decaying debris, and tree bark, and can survive cold temperatures. Conidia may be isolated from the air of the orchard and packaging house, on the walls of the packaging houses, and from the water and fungicide solution into which harvested fruits are dunked before packaging or storage. Exposure to conidia at any step of growth, harvesting, processing, shipping, and storage can lead to inoculation and disease. Conidia that have gained access via a wound can germinate to form a germ tube. This germ tube will continue to grow as hyphae, which colonize the fruit, killing fruit cells in an expanding infection. If the fungus has colonized the fruit with mycelium, the formation of conidiophores occurs on the surface or subsurface of the hyphae. The conidiophores are mostly smooth-walled terverticillate penicilli. A terverticillate pencilii has multiple branch points below the phialides, the cells that the conidia are attached to. However, at times, the penicilli may be rough or biverticillate (only two levels of branching). The phialides are packed close together with nearly a cylindrical shape. The conidia are dry, smooth, elliptical, and "dull-green" in color and are often disseminated by wind currents. Sexual reproduction has not been observed in nature for P. expansum.
Kruja, headquartered at the tekke of Fushë-Krujë Elbasan, headquartered at the tekke of Krastë, Dibër Korça, headquartered at the tekke of Melçan Gjirokastra, headquartered at the tekke of Asim Baba Prishta, representing Berat and part of Përmet Vlora, headquartered at the tekke of Frashër National headquarters in other countries are located in:
== Economy == Bophuthatswana was the richest of the TBVC-states as it had platinum mines, which accounted for two-thirds of the total platinum production in the Western world. It was also rich in asbestos, granite, vanadium, chromium and manganese. Additional revenues came from the Sun City casino, which was a day trip from Johannesburg and Pretoria, where gambling was illegal under the National Party government, as it was throughout all of South Africa. Bophuthatswana had a relatively capitalist free market economy, as seen by the government's drive for infrastructure development, foreign direct investments and virtually no regulatory barriers to starting and running a business. Initially, its economy was driven by agriculture then later by mining, hospitality and banking. Bophuthatswana also issued bearer development bonds. The so-called "Bop Bonds" were redeemed by the government of the North West province from 1995 to 1997, and are now worthless as financial instruments. However, bonds in excellent condition are considered collectible. Bonds issued in 1988 and 1989, in R10 and R20 denominations, currently trade at 10–25% of original face value.
Embryonic mitochondrial transplant and protofection have been proposed as a possible treatment for inherited mitochondrial disease, and allotopic expression of mitochondrial proteins as a radical treatment for mtDNA mutation load. In June 2018 Australian Senate's Senate Community Affairs References Committee recommended a move towards legalising MRT. Research and clinical applications of MRT were overseen by laws made by federal and state governments. State laws were, for the most part, consistent with federal law. In all states, legislation prohibited the use of MRT techniques in the clinic, and except for Western Australia, research on a limited range of MRT was permissible up to day 14 of embryo development, subject to a license being granted. In 2010, the Hon. Mark Butler MP, then Federal Minister for Mental Health and Ageing, had appointed an independent committee to review the two relevant acts: the Prohibition of Human Cloning for Reproduction Act 2002 and the Research Involving Human Embryos Act 2002. The committee's report, released in July 2011, recommended the existing legislation remain unchanged Currently, human clinical trials are underway at GenSight Biologics (ClinicalTrials.gov # NCT02064569) and the University of Miami (ClinicalTrials.gov # NCT02161380) to examine the safety and efficacy of mitochondrial gene therapy in Leber's hereditary optic neuropathy.
=== Colonial Police Medal (CPM) === Chan Pak-chi, Superintendent, Royal Hong Kong Police Force. Albert Chan Ting-kai, Senior Divisional Officer, Royal Hong Kong Police Force. Chan Yun-pui, Senior Divisional Officer, Royal Hong Kong Police Force. Cheung Yuk-fung, Superintendent, Royal Hong Kong Police Force. Paul Croft, Senior Superintendent, Royal Hong Kong Police Force. William Frederick Fenton, Senior Superintendent, Royal Hong Kong Police Force. Gillian Suk-han Fletcher, Chief Inspector, Royal Hong Kong Police Force. Fu Keung San-ling, Sergeant, Royal Hong Kong Police Force. Barry Christopher Griffin, Senior Superintendent, Royal Hong Kong Police Force. Tony Ho Tse-tong, Senior Superintendent, Royal Hong Kong Police Force. Victor Hsu Yung, Senior Divisional Officer, Royal Hong Kong Police Force. Kwan Wa-fai, Station Sergeant, Royal Hong Kong Police Force. Lee Yeung-chi, Superintendent, Royal Hong Kong Police Force. Leung Ping, Station Sergeant, Royal Hong Kong Police Force. Li Chun-wai, Station Sergeant, Royal Hong Kong Police Force. Li Kam-wa, Station Sergeant, Royal Hong Kong Police Force. Li Mau-sau, Station Sergeant, Royal Hong Kong Police Force. Liu Tin-chee, Senior Divisional Officer, Royal Hong Kong Police Force. Lo Chan Lin, Station Sergeant, Royal Hong Kong Police Force. Kenneth William Colin Mackenzie, Superintendent, Royal Hong Kong Police Force. Edward Mak Man-poon, Senior Superintendent, Royal Hong Kong Police Force. Martin Samson, Senior Superintendent, Royal Hong Kong Police Force. Tam Sum-wing, Station Sergeant, Royal Hong Kong Police Force.
Sources: en.wikipedia.org
== Discovery == Islets of Langerhans were first discussed by Paul Langerhans in his medical thesis in 1869. This same year, Édouard Laguesse named them after Langerhans. At first, there was a lot of controversy about what the Islets were made of and what they did. It appeared that all of the cells were the same within the Islet, but were histologically distinct from acini cells. Laguesse discovered that the cells within the Islets of Langerhans contained granules that distinguished them from acini cells. He also determined that these granules were products of the metabolism of the cells in which they were contained. Michael Lane was the one to discover that alpha cells were histologically different than beta cells in 1907. Before the function of alpha cells was discovered, the function of their metabolic product, glucagon, was discovered. The discovery of the function of glucagon coincides with the discovery of the function of insulin. In 1921, Banting and Best were testing pancreatic extracts in dogs that had had their pancreas removed. They discovered that "insulin-induced hypoglycemia was preceded by a transient, rather mild hyperglycemia..." Murlin is credited with the discovery of glucagon because in 1923 they suggested that the early hyperglycemic effect observed by Banting and Best was due to "a contaminant with glucogenic properties that they also proposed to call 'glucagon,' or the mobilizer of glucose". In 1948, Sutherland and de Duve established that alpha cells in the pancreas were the source of glucagon.
The interaction of Western and Japanese music in Meiji era is foremost linked to the military, religious and educational fields. The Japanese assimilated Western culture and its music with the same surprising speed. Music panorama in Japan gradually became lively and prolific where the Western-inspired style music was flourishing.
In the case of neutrophilic pericholangitis, neutrophils surround the portal ducts and obstruct them. Neutrophilic pericholangitis has a variety of causes including endotoxemia, Hodgkin's disease, among others. Cholangitis lenta can also cause changes to the portal tracts. This occurs during chronic cases of sepsis and results in dilation of the bile ductules. Cholangitis lenta is likely a result of a stoppage of bile secretion and bile flow through the ductules. Back pressure created from obstructive cholestasis can cause dilation of the bile duct and biliary epithelial cell proliferation, mainly in the portal tracts. Portal tract edema may also occur as a result of bile retention, as well as periductular infiltration of neutrophils. If the obstruction is left untreated, it can lead to a bacterial infection of the biliary tree. Infection is mostly caused by coliforms and enterococci and is evident from a large migration of neutrophils to the duct lumina. This can result in the formation of a cholangitic abscess. With treatment, many of the histological features of cholestasis can be corrected once the obstruction is removed. If the obstruction is not promptly resolved, portal tract fibrosis can result. Even with treatment, some fibrosis may remain.
Jasleen Kaur is named as the winner of the 2024 Turner Prize. 4 December Cheshire Constabulary confirms they have interviewed Lucy Letby under caution in prison about further baby deaths. The former prime minister, Boris Johnson, accuses Starmer of misleading the House of Commons and says he should correct the record immediately. This follows an exchange in the House during PMQs when Starmer, answering a question from the leader of the opposition, Kemi Badenoch, said that "two of her predecessors had convictions for breaking the Covid rules". Although the former Conservative prime ministers, Johnson and Rishi Sunak had received fixed penalty notices for breaking COVID-19 regulations, neither had any criminal convictions. 5 December – The Princess of Wales hosts her annual Christmas carol service at Westminster Abbey. 6 December Data published by the Halifax Bank indicates house prices rose by 1.3% in November 2024, marking the fifth consecutive month of growth, with the average house price now estimated at £298,083. Around three million people in Wales and South West England are sent emergency alerts as Storm Darragh approaches the UK. The owners of The Observer confirm the newspaper has been sold to Tortoise Media. The Royal Mint unveils a collector's edition £5 coin featuring Sir Paul McCartney. The UK government announces a £500m contract to build 14 "state-of-the-art" trains at Hitachi's Newton Aycliffe factory, securing the facility's future.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.